LONDON, UK: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), today announced the launch of Salistick™, the first-ever saliva pregnancy test, in the UK and Ireland.

Salistick™ offers women an improved user experience, with high accuracy for early pregnancy detection, by way of its revolutionary and patented saliva technology which allows for saliva to be used as a sample rather than the traditional urine tests. Salistick™ offers the ability to test anywhere, anytime, and for the testing experience to be shared with a partner and other loved ones.

Abingdon is the exclusive distributor of Salistick™ in the UK and Ireland on behalf of Salignostics Ltd, an Israeli developer of innovative saliva-based diagnostics tests. As well as providing distribution support, Abingdon has been providing Salignostics with contract development services in scaling-up the Salistick™ product for manufacture and will continue to provide Salignostics with contract manufacturing services going forward.

Abingdon is launching Salistick™ with Superdrug, a leading health and beauty retailer in the United Kingdom, initially rolling out into 400 stores and online at Superdrug.com. Superdrug trades from almost 900 stores across the United Kingdom and Ireland.

In addition, Salistick™ will also launch through Abingdon’s direct-to-consumer e-commerce channel Abingdon Simply Test. Salistick™ is co-branded Abingdon Simply Test™, with the Abingdon Simply Test™ range now including over 15 self-tests. Abingdon intends to continue expanding the range of innovative self-tests it makes available to consumers through partnering with companies such as Salignostics Ltd to offer the very best in novel self-test technology to the market.

Chris Yates, CEO of Abingdon Health plc, commented: “We are delighted to announce the launch of Salistick™ initially across 400 Superdrug stores and at Superdrug.com. This novel technology provides women with an enhanced user-experience; offering the ability to test anywhere, anytime, and for the experience to be shared with a partner and other loved ones. We are pleased to have supported our partner Salignostics Ltd through the development process into manufacturing and now commercial launch, and we look forward to deepening our collaboration as we move forward.”

The launch of Salistick™ is a significant development in the pregnancy testing market, which is expected to grow at a CAGR of 5.08% from 2022 to 2028. Salistick™ offers a number of advantages over traditional urine-based pregnancy tests, including:

• Increased convenience: Salistick™ can be taken anywhere, anytime, without the need to collect a urine sample.
• Improved accuracy: Salistick™ has been shown to be as accurate as traditional urine-based pregnancy tests.
• Enhanced user experience: Salistick™ is easy to use and the results are clear and easy to understand.

The launch of Salistick™ is a welcome addition to the pregnancy testing market and is likely to appeal to women who are looking for a convenient, accurate, and easy-to-use pregnancy test.

Abingdon Health signs manufacturing agreement with Bioporto A/S